Novonesis stock heads into the open after a 1.2% drop
Published on 09/18/2026 at 04:38 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
At the close on September 17, 2026, Novonesis stock finished at DKK 426.80 on Nasdaq Copenhagen, down 1.2% compared with the prior trading day. The move left the shares trading below the reference level used for the company’s first share buyback tranche, keeping the buyback programme in focus ahead of today’s session.
September 17, 2026 in numbers
Novonesis Inc. (ISIN DK0060336014) is primarily listed on Nasdaq Copenhagen, where its shares trade in Danish kroner as part of the main Danish equity indices. Per recent Nasdaq Copenhagen data cited by Nordnet, the B shares closed at DKK 426.80 on September 17, 2026, after a 1.2% decline on the day, within an intraday range that placed the close between the session’s low and high.Nordnet The price level was below the recent closing share price of DKK 275.90 referenced for the initial share repurchase tranche, once converted for the programme’s structure, underscoring how the stock has moved since that benchmark was set.ad-hoc-news
According to a corporate news report distributed via Via Ritzau and summarized by ad-hoc-news, Novonesis recently launched a share buyback programme with a first tranche of up to EUR 75 million, expected to run no later than December 17, 2026 and corresponding to roughly 1.3 million B shares based on the closing share price on September 11, 2026. The report noted that Novonesis stock trades near levels that reflect its 52-week performance range and forms part of key Danish equity indices, making the buyback an important factor for trading activity. Commentary from an investment manager cited by the Financial Times indicated that a holding in Novonesis contributed positively to portfolio performance after stronger-than-expected organic sales growth and a raised full-year outlook, with management lifting organic growth guidance to 7-8% and signaling confidence in delivering toward the upper end of its EBITDA margin range.Financial Times Against that backdrop, the 1.2% decline on September 17, 2026 left the share price softer on the day while longer-term guidance and capital-return plans remained supportive in the background.
Today’s focus for Novonesis
Today, investors can continue to weigh Novonesis against the broader European equity environment, where recent portfolio commentary highlighted the company’s role in supporting returns after delivering stronger organic growth and raising its outlook.Financial Times The ongoing share buyback programme, with its first tranche scheduled to run until December 17, 2026, remains a potential driver of trading volumes and price support as the company repurchases B shares within the parameters outlined in its announcement.ad-hoc-news In addition, the raised full-year guidance and focus on maintaining attractive margins and returns, as described in recent portfolio commentary, provide further context for how the stock may respond to sector and macro developments in the coming sessions.Financial Times
